Investing
Sarepta tumbles 15% on 9001 decision delay; analysts see a buying opportunity
© Reuters. Sarepta (SRPT) tumbles 15% as FDA needs more time to complete a review of SRP-9001
Sarepta Therapeutics (NASDAQ:) shares fell as much as 14.8% in early Wednesday trading after the medical research company said the U.S. Food and Drug Administration (FDA) informed the company it “requires modest additional time to complete the review” of SRP-9001.
Hence, the PDUFA date for ‘9001 will be delayed until June 22, 2023, from May 29th.
The therapy is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD).
The company said the FDA also indicated that it intends to potentially grant an accelerated approval for SRP-9001, initially for use in Duchenne patients ages 4-5 years old, once the review is completed.
RBC analysts said the delay “offers concrete timelines.”
“Although initial potential label limitation is a slight disappointment, we see limited effect on ‘9001’s medium/long-term opportunity and remain believers into EMBARK and on ‘9001’s long-term prospects. As such, we believe weakness presents a buying opportunity.”
Read the full article here
-
Passive Income6 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles5 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles6 days ago
How Your Body Language Can Help Win a Disagreement
-
Investing6 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles6 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles4 days ago
Mark Zuckerberg Is Now Second Richest Person in the World
-
Investing4 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Passive Income5 days ago
How AI-Driven Personalization Is Transforming the Retail Industry